Rapidscan Pharma Solutions Inc. has been acquired by GE Healthcare
The shareholders of Rapidscan Pharma Solutions, Inc. (Rapidscan) have sold the company to GE Healthcare, a global provider of contrast media, medical technologies and services, and biomanufacturing solutions. Financial details have not been disclosed.
Rapidscan is a privately held healthcare company specializing in the production of Rapiscan®, a selective coronary vasodilator for radionuclide myocardial perfusion imaging. The company was founded in 2010 by leading members of the team that discovered and developed regadenoson, a new pharmacological stress agent used in the diagnosis and risk stratification of cardiovascular disease.
Headquartered in Chicago, GE Healthcare is a unit of General Electric Company (NYSE: GE). GE Healthcare is a global provider of contrast media, medical technologies and services, and biomanufacturing solutions. GE Healthcare has acquired the exclusive rights from Rapidscan to produce and sell the pharmacological stress agent Rapiscan® (Regadenoson) in territories outside the USA, Canada and Mexico.
Oaklins Cavendish, based in the UK, advised Radpidscan on its acquisition by GE Healthcare. Oaklins Cavendish has considerable experience in advising pharmaceutical and healthcare businesses. The team's specialist commented: “We are delighted to have advised the shareholders of Rapidscan and to have found in GE Healthcare the right buyer to continue to expand Rapidscan’s growing network of markets outside of North America. This acquisition will see Rapidscan and GE Healthcare unlock significant synergies from their complementary geographical reach and will meet the growing demand for Rapidscan’s specialist product.”
Talk to the deal team
Related deals
CARSO Group has acquired a majority stake in AQCF Group
CARSO Group, a leading provider of testing services, has acquired a majority stake in AQCF Group, a key player in the field of food safety.
Learn morePrestige Inhome Care has found a long-term strategic partner
Prestige Inhome Care has received a growth capital investment from Yorkway Private. The newly formed partnership will provide growth capital for geographic expansion, increasing Prestige’s range of services and potential future acquisitions. The investment in Prestige is in line with Yorkway’s mandate to invest in leading Australian mid-market companies with strong management teams, backed by significant growth tail winds, as is the case in the aged care industry.
Learn moreCara Care has been acquired by Mahana Therapeutics
Mahana Therapeutics Inc., renowned for its pioneering digital treatments targeting chronic health issues, has recently finalized the acquisition of Cara Care (HiDoc Technologies GmbH). Cara Care stands out as a premier digital health platform and an official digital health application (DiGA) dedicated to enhancing gut health. This acquisition, supported by key investors Lux Capital and Jazz Ventures Partners, perfectly aligns with Mahana’s expansion strategy.
Learn more